Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion type Assertion NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_head.
- NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion description "[Here we asked whether Interleukin(IL)-27, which has revealed powerful antitumor activity and is toxicity-free in humans, is a promising therapeutic choice for NSCLC patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_provenance.
- NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion evidence source_evidence_literature NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_provenance.
- NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion SIO_000772 25638163 NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_provenance.
- NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion wasDerivedFrom befree-2016 NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_provenance.
- NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_assertion wasGeneratedBy ECO_0000203 NP1259820.RAUc1MGLJ9Uq6EKMIyTNoh24AlLA3c1YHxk3W1jiJFH-M130_provenance.